Skip to content

Study · Not a test of the peptide alone · 2009

1 result

Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA.

Coch C, Busch N, Wimmenauer V, Hartmann E, Janke M, Abdel-Mottaleb MM, Lamprecht A, Ludwig J, Barchet W, Schlee M, Hartmann G

Journal of leukocyte biology20 Jul 2009Cited by 29 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LL-37.

  1. 01LabNot a test of LL-37 aloneIn vitro (cells)Mechanism

    In human plasmacytoid dendritic cells, activation by phosphodiester ODNs and genomic DNA required complexation with cationic molecules such as LL37 or a scrambled derivative.

    In plain wordsIn cells, DNA activated immune cells only when bound to cationic molecules such as LL37, used here as a tool.

    Peptide
    LL-37
    Outcome
    Not applicableNeed for cationic complexation for DNA activation of PDC
    Study

    humann: not reported in source

    human plasmacytoid dendritic cells (PDC)
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    For activation of PDC, phosphodiester ODNs and genomic DNA strictly required complexation with cationic molecules such as the keratinocyte-derived antimicrobial peptide LL37 or a scrambled derivative.

    In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LL-37.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:58 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.